Do we need 'new' omega-3 polyunsaturated fatty acids formulations?

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 3, 2015, Pages 285-288

  Cicero, Arrigo F G ^a,b   Morbini, Martino ^a   Borghi, Claudio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Poliambulatorio Pad 2   (Italy)

Author keywords

Bioavailability; Docosahexaenoic acid; Eicosapentaenoic acid; Fish oil; Polyunsaturated fatty acid

Indexed keywords

OMEGA 3 FATTY ACID; DOCOSAHEXAENOIC ACID; FATTY ACID; FISH OIL; ICOSAPENTAENOIC ACID;

CARDIOVASCULAR DISEASE; DRUG BIOAVAILABILITY; DRUG FORMULATION; HUMAN; MEDICAL RESEARCH; REVIEW; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; ANIMAL; CARDIOVASCULAR DISEASES; CHEMISTRY; DIET SUPPLEMENTATION;

ANIMALS; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACIDS, NONESTERIFIED; FATTY ACIDS, OMEGA-3; FISH OILS;

EID: 84921481770     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.991308     Document Type: Review

References (15)

1. Cicero AF, Reggi A, Parini A, et al. Application of polyunsaturated fatty acids in internal medicine: beyond the established cardiovascular effects. Arch Med Sci 2012;8(5):784-93
2. Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308(10):1024-33
3. Casula M, Soranna D, Catapano AL, et al. Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: a meta-analysis of randomized, placebo controlled trials. Atheroscler Suppl 2013;14(2):243-51
4. Gao LG, Cao J, Mao QX, et al. Influence of omega-3 polyunsaturated fatty acid-supplementation on platelet aggregation in humans: a meta-analysis of randomized controlled trials. Atherosclerosis 2013;226(2):328-34
5. Lev EI, Solodky A, Harel N, et al. Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. J Am Coll Cardiol 2010;55(2):114-21
6. Cicero AF, Ertek S, Borghi C. Omega-3 polyunsaturated fatty acids: their potential role in blood pressure prevention and management. Curr Vasc Pharmacol 2009;7(3):330-7
7. Zhou Y, Tian C, Jia C. Association of fish and n-3 fatty acid intake with the risk of type 2 diabetes: a meta-analysis of prospective studies. Br J Nutr 2012;108(3):408-17
8. Hooper L, Thompson RL, Harrison RA, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. Brit Med J 2006;332:752-60
9. Harris WS. Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am J Cardiol 2007;99(6A):44C-6C
10. Guallar E, Sanz-Gallardo MI, van't Veer P, et al. Mercury, fish oils, and the risk of myocardial infarction. Heavy Metals and Myocardial Infarction Study Group. N Engl J Med 2002;347(22):1747-54
11. Cohen JT, Bellinger DC, Connor WE, et al. A quantitative risk-benefit analysis of changes in population fish consumption. Am J Prev Med 2005;29(4):325-34
12. Harris WS, Pottala JV, Sands SA, et al. Comparison of the effects of fish and fish oil capsules on the n-3 fatty acid content of blood cells and plasma phospholipids. Am J Clin Nutr 2007;86(6):1621-5
13. Di Minno MN, Tremoli E, Tufano A, et al. Exploring newer cardioprotective strategies: w-3 fatty acids in perspective. Thromb Haemost 2010;104(4):664-80
14. Roth EM. Eicosapentaenoic acid + docosahexaenoic acid for the treatment of severe hypertriglyceridemia. Exp Opin Pharmacother 2014. [Epub ahead of print]
15. Blair HA, Dhillon S. Omega-3 carboxylic acids (Epanova): a review of its use in patients with severe hypertriglyceridemia. Am J Cardiovasc Drugs 2014;14(5):393-400